Clinical scoring systems to estimate the probability of severe ADAMTS13 deficiency in patients with TMA.
| French score | PLASMIC score | |
|---|---|---|
| Platelet count | ≤30×109 L: +1 | <30×109 L: +1 |
| Creatinine level | ≤2.26 mg/dL: +1 | <2.0 mg/dL: +1 |
| Hemolysis variablea) | +1 | |
| No active cancer | +1 | |
| No history of solid-organ or stem-cell transplantation | +1 | |
| MCV <90 Fl | +1 | |
| INR <1.5 | +1 | |
| ANA | +1 | |
| Total score and likelihood of TTP | 0: 2% | 0–4 (low risk): 0–4% |
| 1: 70% | 5 (intermediate risk): 9–24% | |
| 2–3: 94% | 6–7 (high risk): 62–82% |
a)Reticulocyte count >2.5%, undetectable haptoglobin, or indirect bilirubin >2.0 mg/dL. Abbreviations: MCV, mean corpuscular volume; INR, international normalized ratio; ANA, antinuclear antibody.
Blood Res 2022;57:S37~S43 https://doi.org/10.5045/br.2022.2022005
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd